Nature Communications (Feb 2025)
Harnessing macrophage-drug conjugates for allogeneic cell-based therapy of solid tumors via the TRAIN mechanism
- Bartlomiej Taciak,
- Maciej Bialasek,
- Malgorzata Kubiak,
- Ilona Marszalek,
- Malgorzata Gorczak,
- Olha Osadchuk,
- Daria Kurpiel,
- Damian Strzemecki,
- Karolina Barwik,
- Marcin Skorzynski,
- Julia Nowakowska,
- Waldemar Lipiński,
- Łukasz Kiraga,
- Jan Brancewicz,
- Robert Klopfleisch,
- Łukasz Krzemiński,
- Emilia Gorka,
- Anna Smolarska,
- Irena Padzinska-Pruszynska,
- Małgorzata Siemińska,
- Jakub Guzek,
- Jan Kutner,
- Marlena Kisiala,
- Krzysztof Wozniak,
- Giacomo Parisi,
- Roberta Piacentini,
- Luca Cassetta,
- Lesley M. Forrester,
- Lubomir Bodnar,
- Tobias Weiss,
- Alberto Boffi,
- Paulina Kucharzewska,
- Tomasz P. Rygiel,
- Magdalena Krol
Affiliations
- Bartlomiej Taciak
- Cellis AG
- Maciej Bialasek
- Cellis AG
- Malgorzata Kubiak
- Cellis AG
- Ilona Marszalek
- Cellis AG
- Malgorzata Gorczak
- Cellis AG
- Olha Osadchuk
- Cellis AG
- Daria Kurpiel
- Cellis AG
- Damian Strzemecki
- Cellis AG
- Karolina Barwik
- Cellis AG
- Marcin Skorzynski
- Department of Immunology, Mossakowski Medical Research Institute, Polish Academy of Sciences
- Julia Nowakowska
- Cellis AG
- Waldemar Lipiński
- Cellis AG
- Łukasz Kiraga
- Cellis AG
- Jan Brancewicz
- Cellis AG
- Robert Klopfleisch
- Institute of Veterinary Pathology, Free University of Berlin
- Łukasz Krzemiński
- Biosens Labs Sp. z o.o
- Emilia Gorka
- Cellis AG
- Anna Smolarska
- Center of Cellular Immunotherapies, Warsaw University of Life Sciences
- Irena Padzinska-Pruszynska
- Center of Cellular Immunotherapies, Warsaw University of Life Sciences
- Małgorzata Siemińska
- Cellis AG
- Jakub Guzek
- Center of Cellular Immunotherapies, Warsaw University of Life Sciences
- Jan Kutner
- The International Institute of Molecular Mechanisms and Machines, Polish Academy of Sciences
- Marlena Kisiala
- Department of Chemistry, Biological and Chemical Research Centre, University of Warsaw
- Krzysztof Wozniak
- Department of Chemistry, Biological and Chemical Research Centre, University of Warsaw
- Giacomo Parisi
- Department of Biochemical Sciences “Alessandro Rossi Fanelli”, Sapienza University of Rome
- Roberta Piacentini
- Department of Biochemical Sciences “Alessandro Rossi Fanelli”, Sapienza University of Rome
- Luca Cassetta
- MRC Centre for Reproductive Health, Queen Medical Research Institute, University of Edinburgh
- Lesley M. Forrester
- Centre for Regenerative Medicine, University of Edinburgh
- Lubomir Bodnar
- Cellis AG
- Tobias Weiss
- Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich
- Alberto Boffi
- Cellis AG
- Paulina Kucharzewska
- Cellis AG
- Tomasz P. Rygiel
- Cellis AG
- Magdalena Krol
- Cellis AG
- DOI
- https://doi.org/10.1038/s41467-025-56637-9
- Journal volume & issue
-
Vol. 16,
no. 1
pp. 1 – 30
Abstract
Abstract Treatment of solid tumors remains challenging and therapeutic strategies require continuous development. Tumor-infiltrating macrophages play a pivotal role in tumor dynamics. Here, we present a Macrophage-Drug Conjugate (MDC) platform technology that enables loading macrophages with ferritin-drug complexes. We first show that macrophages actively take up human heavy chain ferritin (HFt) in vitro via macrophage scavenger receptor 1 (MSR1). We further manifest that drug-loaded macrophages transfer ferritin to adjacent cancer cells through a process termed ‘TRAnsfer of Iron-binding protein’ (TRAIN). The TRAIN process requires direct cell-to-cell contact and an immune synapse-like structure. At last, MDCs with various anti-cancer drugs are formulated with their safety and anti-tumor efficacy validated in multiple syngeneic mice and orthotopic human tumor models via different routes of administration. Importantly, MDCs can be prepared in advance and used as thawed products, supporting their clinical applicability. This MDC approach thus represents a promising advancement in the therapeutic landscape for solid tumors.